This study outcome closely mirror the findings of the WHO REACT [62] group, indicating that the use of IL-6 antagonists such as Tocilizumab and Sarilumab in COVID-19 patients may reduce 28-day mortality, with an OR of 0.86 and a 95% CI of 0.79–0.95 (p=0.003). Here, IL6 is linked to COVID-19.